Helping to advance the scientific understanding of some of the world’s most devastating diseases, Protagen’s research activities have resulted in a number of key peer-reviewed publications on autoimmune diseases and immuno-oncology.
Protagen is engaged in a number of research projects both independently and in collaboration with our partners across the globe, to help accelerate the development of precision diagnostics solutions. Through this work, Protagen has contributed to a number of scientific papers and application notes on autoimmune diseases and immuno-oncology. For more information about our research programs, please contact us.
- Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis (external link)
- Multiparametric detection of autoantibodies in systemic lupus erythematosus (external link)
- A multicenter photoprovocation study to identify potential biomarkers by global peptide profiling in cutaneous lupus erythematosus (external link)
As part of our mission to advance the treatment of cancer and autoimmune diseases, we have analyzed the immune responses of over 20,000 patients and healthy controls, leading to a unique, comprehensive, and permanently growing database.
Protagen’s Dr Peter Schulz-Knappe and Dr Georg Lautscham discuss why carefully monitoring the balance between immune repression and stimulation during cancer immunotherapy will lead to the development of more successful treatments, and suggest why autoantibodies are already showing great promise as powerful tools in this process.
Here you can see some of Protagen’s most recent conference presentations and posters, where the company’s latest advancements in disease research have been shared with delegates from around the world.
Here you will find a number of our visual resources that help explain some of the disease areas we work in, and the challenges we are overcoming. From animations to whitepapers and eBooks, see below for a number of downloadable resources.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.